Counterfeit versions of Nordic Bioscience's PRO-C3 biochemical assay have recently entered circulation globally.
Please be advised that all published data is exclusively based on Nordic Bioscience developed assays and the use of potentially uncertified assays may lead to incoherent and unqualified results.
If you have doubts about the originality of an assay, consider asking these questions:
What data support the use of these biomarkers?
A biomarker is only as good as the data that supports it. Nordic Bioscience has invested the last 25 years in research to develop unique and proprietary blood-based biomarkers for chronic diseases. We have published and validated the biomarkers in over 600 articles in peer-reviewed journals such as Nature, The Lancet, ERJ and many others.
Are these biomarkers patented and validated?
To protect your translational and clinical science, do not measure assays that are not supported by strong scientific research and extensive validation. Nordic Bioscience has developed and invested in patented monoclonal antibodies based on our unique neo-epitope platform.
Are these biomarkers measured in an approved environment?
We always recommend testing under CAP accreditation and CLIA compliance.Nordic Bioscience measures biomarkers in our CAP-certified laboratory, which follows CLIA guidelines and provides a set of services and procedures that must be met to achieve the highest quality. Biomarkers such as PRO-C3 and PRO-C6 have been transferred to the Roche Cobas platform, which offer high precision and robustness.
We do not condone these counterfeit versions of our assays on the market and strongly discourage our customers from purchasing them. Nordic Bioscience is currently investigating whether we need to take legal action. If you have any concerns, please contact us at bd@nordicbio.com.
